Covid Info

Your Partner in Clinical Research

We are a caring, dedicated, and experienced team driven by quality and a passion for changing diabetes. Our research staff, with more than 70 years of combined research experience and 100+ studies started, works collaboratively with our research partners to efficiently recruit and retain patients in clinical trials.

Site Strengths

  • Experienced research coordinators with a special interest in diabetes
  • Experienced investigators with 100+ clinical trials started
  • High-quality research performance (FDA audit in 2017 with no findings)
  • First ever research-based patient portal
  • Multiple community relationships providing referrals for research
  • Ability to use a Central IRB
  • Clinical trial management software ensuring efficient organization of all research activities

Interested in Partnering?

We are always looking for new research opportunities. Please leave your contact information below and a member of our business development team will reach out to you shortly.

Please enter your first name.
Please enter your last name.
Please enter your valid phone number.
Please enter your valid email.
Please enter a sponsor name.
Please enter medical condition.
Please enter your comments.

We are a multi-center site in Central Iowa performing research in diabetes, diabetes-related conditions, and hormonal disorders.

Type 2 Diabetes
Type 1 Diabetes
Pumps, CGMs, Glucose Meters
Kidney Disease
Men’s Health (Low-T & Erectile Dysfunction)
Cardiovascular Disease

Partners We’ve Worked With

Recruitment History

Iowa Diabetes Research has a strong history of success in trial recruitment, having over-recruited for a majority of studies we have done to date.
Our Patient Qualifier platform allows us to efficiently and effectively recruit study participants using real-time health data and communication features.
Most of our research patients join another study with us after they finish their current study because of our caring, passionate, and patient-centered staff.
Company/Medication Enrollment Goal Screened Randomized % Enrollment
Medtronic/Pump use in T1D 12 51 41 342%
GlaxoSmithKline/CV outcomes 10 31 28 280%
Gan and Lee/ Biosimilar insulin glargine in T2D 12 31 23 192%
Lilly/T2DM ultra rapid acting formula insulin lispro 8 24 13 163%
Gan and Lee/ Biosimilar insulin glargine in T1D 12 27 19 158%
Novo Nordisk/GLP-1 use for treatment of obesity 7 16 11 157%
Lilly/T1DM ultra rapid acting formula insulin lispro 13 31 19 146%
Boehringer Ingelheim/SGLT-2 in T1D 36 50 48 133%
Dexcom/CGM use in T1D and T2D 50 59 55 110%

Testimonials From Monitors

Have questions? Call us at (515) 329-6800 or email us at